GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anterogen Co 065660.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

13,140

+4.29%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩7.54bn

FY2016FY2025

Net income

−₩1.37bn

FY2016FY2025

Free cash flow

−₩1.29bn

FY2016FY2025

Shareholders' equity

₩87.45bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩7.54bn₩6.93bn₩6.50bn₩6.59bn₩8.12bn₩4.15bn₩4.15bn₩3.61bn₩5.36bn₩4.90bn
Research and development₩3.09bn₩4.11bn₩5.38bn₩4.66bn₩4.19bn₩4.01bn₩2.53bn₩1.87bn₩1.01bn₩1.55bn
Operating income−₩2.43bn−₩3.80bn−₩5.46bn−₩6.25bn−₩2.63bn−₩2.74bn−₩4.73bn−₩2.49bn−₩143.0m₩102.6m
Net income−₩1.37bn−₩2.29bn−₩2.84bn−₩6.84bn−₩554.0m−₩4.38bn−₩4.05bn−₩961.8m₩446.7m₩371.7m
Diluted earnings per share-137.30-235.61-291.93-702.58-58.80-481.12-476.17-113.9656.1749.80

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩88.26bn₩116.08bn₩149.43bn₩124.13bn₩136.70bn₩94.20bn₩84.59bn₩101.44bn₩58.14bn₩35.43bn
Cash and short-term investments———₩55.97bn₩59.01bn₩47.92bn₩50.03bn₩55.90bn₩34.38bn₩22.39bn
Total liabilities₩812.6m₩5.87bn₩19.99bn₩17.34bn₩19.83bn₩13.14bn₩16.20bn₩45.37bn₩11.53bn₩1.40bn
Debt———₩12.71bn₩11.77bn₩9.25bn₩13.27bn₩39.82bn₩9.32bn—
Shareholders' equity₩87.45bn₩110.21bn₩129.44bn₩106.79bn₩116.87bn₩81.07bn₩68.39bn₩56.07bn₩46.61bn₩34.02bn
Shares outstanding10m10m10m10m9m9m9m8m8m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩1.02bn−₩860.4m−₩1.99bn−₩1.98bn−₩3.05bn−₩4.41bn−₩1.65bn−₩1.50bn₩379.2m−₩130.6m
Capital spending−₩265.8m−₩311.6m−₩203.3m−₩1.48bn−₩3.33bn−₩5.72bn−₩2.99bn−₩3.55bn−₩637.5m−₩6.06bn
Free cash flow−₩1.29bn−₩1.17bn−₩2.19bn−₩3.46bn−₩6.38bn−₩10.13bn−₩4.64bn−₩5.06bn−₩258.3m−₩6.19bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩2.20bn₩2.12bn₩2.00bn₩2.04bn₩1.89bn₩1.60bn₩1.79bn₩1.90bn
Operating income−₩477.8m−₩1.10bn−₩474.9m−₩407.4m−₩454.7m−₩1.10bn−₩1.30bn−₩637.0m
Net income−₩149.9m−₩882.3m−₩505.6m−₩79.3m−₩90.1m−₩698.8m−₩1.04bn−₩162.4m
Diluted earnings per share-14.98-88.17-50.53-7.93-9.01-69.83-107.12-16.69
Cash from operations₩1.0m−₩812.0m−₩584.0m₩281.0m−₩134.0m−₩582.0m−₩860.0m−₩475.0m
Capital spending−₩128.0m−₩109.0m−₩66.0m−₩27.0m−₩61.0m−₩110.0m−₩311.0m−₩180.0m
Free cash flow−₩127.0m−₩921.0m−₩650.0m₩254.0m−₩195.0m−₩692.0m−₩1.17bn−₩655.0m
Total assets₩82.62bn₩84.79bn₩88.26bn₩91.44bn₩91.84bn₩96.17bn₩116.08bn₩115.89bn
Cash and short-term investments———————₩39.92bn
Shareholders' equity₩80.41bn₩83.83bn₩87.45bn₩90.04bn₩90.69bn₩94.30bn₩110.21bn₩112.51bn

Financial ratios

Data as of 2 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating margin-32.3%-54.9%-83.9%-94.8%-32.4%-66.1%———
Net margin-18.2%-33.1%-43.7%-103.7%-6.8%-105.4%———
Return on equity-1.6%-2.1%-2.2%-6.4%-0.5%-5.4%———
Return on assets-1.6%-2.0%-1.9%-5.5%-0.4%-4.6%———
Free cash flow yield——————1.1%1.6%0.9%
Revenue growth8.7%6.7%-1.4%-18.8%95.6%0.1%———
Earnings growth-40.1%-19.3%-58.4%1134.2%-87.3%8.0%———
Current ratio78.12x30.42x5.24x4.15x4.75x4.70x———
Debt to equity———0.00x0.00x0.00x0.00x0.18x0.20x
Equity ratio99.1%94.9%86.6%86.0%85.5%86.1%———
Interest coverage—-14.66x-3.58x-3.69x-2.12x-8.69x-7.06x——
R&D as a share of sales41.0%59.2%82.8%70.7%51.6%96.5%———
Buybacks as a share of market value——————-0.8%-6.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.6%12.7%7.9%
Operating income-27.0%-2.4%34.5%
Net income-41.4%-20.7%37.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-43.1%-65.1%-58.5%-50.0%
Net margin-25.3%-48.4%-45.9%-36.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-341.2-80.2-58.5-20.9-1093.6-129.5-90.1-620.4—475.9
Price to sales62.226.525.621.774.6136.588.0165.468.336.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.